AQP4 and myasthenia gravis: Supplementary Figure S5 shows that the NMOSD targeted immunotherapy have been first published since 2004, the cause of this phenomenon is the discovery of AQP4 (aquaporin 4) antibody in 2005 (44), NMOSD was independent from MS, and the public had a new understanding of the pathogenesis of NMOSD. Since then, biological agents for various targets on its pathogenesis have been developed. Supplementary Figure S6 shows that the publication outputs of targeted immunotherapy for MS is highly than NMOSD and MG and shows a continuous growth trend.